Librela

Librela® Injection (Bedinvetmab): Targeted Monthly Relief for Canine Osteoarthritis Pain

Librela® is a breakthrough prescription treatment for the alleviation of chronic pain associated with osteoarthritis (OA) in dogs. This innovative therapy utilizes a canine therapeutic monoclonal antibody (mAb) to provide effective, targeted pain relief.

Key Mechanism of Action

• Targeted Relief: The active ingredient, Bedinvetmab, works by neutralizing Nerve Growth Factor (NGF), a key protein involved in the transmission and sensitization of pain signals in the body.

• Convenience: Administered via subcutaneous injection on a routine schedule, providing long-lasting, consistent relief without daily oral medication.

Product Details

• Active Ingredient: Bedinvetmab

• Approved Species: Dog

• Uses: Analgesic

• Form: Solution for Subcutaneous administration (injection).

Prescription and Administration Required

Librela® is a prescription-only medication. A valid veterinary prescription is required for purchase. This product is typically administered by a veterinarian or trained staff.